azelastine ophthalmic / Generic mfg. - LARVOL DELTA

Clinical and Biological Evaluation of NAAGA Versus Azelastine Eye Drops in Allergic Subjects With Tear Film Dysfunction (clinicaltrials.gov) - P4 | N=134 | Completed | Sponsor: Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona

New P4 trial • Conjunctivitis • Dry Eye Disease • Ocular Infections • Ocular Inflammation • Ophthalmology

A Study to Evaluate the Efficacy and Safety of Epinastine Hydrochloride Eye Drops in the Treatment of Chinese Seasonal Allergic Conjunctivitis Patients (clinicaltrials.gov) - P3 | N=266 | Completed | Sponsor: Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.

New P3 trial • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology

Synchronous Fluorescence as a Green and Selective Method for the Simultaneous Determination of Cetirizine and Azelastine in Aqueous Humor. (PubMed, J Fluoresc) - "The mean percentage of recoveries of CTZ and AZE in spiked aqueous humor were 99.83 and 99.37, respectively. Furthermore, Green Analytical Procedure Index (GAPI) and analytical Eco-scale approaches were used to evaluate the greenness of the suggested method."

Journal

[VIRTUAL] MP-AzeFlu improves allergic rhinitis severity regardless of disease phenotype a real-life study (EAACI 2020) - "MP-AzeFlu (137 g azelastine hydrochloride + 50 g fluticasone propionate intranasal spray) is a treatment for AR but the effectiveness of MP-AzeFlu on disease severity by AR phenotypes is unknown. MP-AzeFlu was associated with reduced severity based on VAS scores from baseline in the general study population and in all ARPs. These results support the effectiveness of MP-AzeFlu for moderate-to-severe AR, regardless of IgE response, family history of allergy, and presence of comorbidities."

Clinical • Allergic Rhinitis • Allergy • Immunology

DYNAS-CHI: DYmista NAsal Spray in CHInese Patients (clinicaltrials.gov) - P3; N=900; Completed; Sponsor: MEDA Pharma GmbH & Co. KG; Recruiting ➔ Completed; Trial completion date: Dec 2019 ➔ Sep 2019

Clinical • Trial completion • Trial completion date

DYNAS-CHI: DYmista NAsal Spray in CHInese Patients (clinicaltrials.gov) - P3; N=900; Recruiting; Sponsor: MEDA Pharma GmbH & Co. KG; Trial completion date: Jul 2019 ➔ Dec 2019; Trial primary completion date: Jul 2019 ➔ Dec 2019

Clinical • Trial completion date • Trial primary completion date

Real-life effectiveness of MP-AzeFlu in Irish patients with persistent allergic rhinitis, assessed by visual analogue scale and endoscopy. (PubMed, Immun Inflamm Dis) - "MP-AzeFlu provided effective, rapid control of PER as assessed by VAS in a real-world clinical setting in Ireland. Symptom improvement was observed at Day 1, sustained for 42 days, and associated with improved mucosal appearance after 28 days. These results confirm the safety of MP-AzeFlu and exceed the efficacy demonstrated in phase 3 clinical studies for controlling AR in PER patients."

Clinical • Journal

The complex pathophysiology of allergic rhinitis: scientific rationale for the development of an alternative treatment option. (PubMed, Allergy Asthma Clin Immunol) - "In particular, we consider how a new AR preparation, MP-AzeFlu (Dymista, Meda, Sweden), comprising a formulation of an intranasal antihistamine (azelastine hydrochloride), an intranasal corticosteroid (fluticasone propionate), and excipients delivered in a single spray, may offer benefits over and above single and multiple AR therapy options. We review the evidence in support of this treatment across the spectrum of AR disease. The concept of AR control is also reviewed within the context of new European Union and Contre les Maladies Chroniques pour un VIeillissement Actif-Allergic Rhinitis and its Impact on Asthma initiatives."

Journal • Review